2026· Advances in Pharmacology· Vol 106, pp.
141-177
· 0 citations
Medicine
TL;DR
This review underscores that optimizing T-cell therapy requires treating manufacturing not as a logistical necessity but as a controllable biological intervention, and a mechanistic understanding of how processing decisions program cellular behavior will enable the rational design of more potent, durable, and scalable T-cell products for diverse clinical applications.
Dysregulation of the immune system drives a broad spectrum of diseases, including cancers, autoimmune disorders, and neuro-immune conditions. Immunotherapy has advanced from small-molecule drugs to biomacromolecular agents and living cell therapies, yet conventional synthetic delivery platforms struggle to preserve the...
Xi Tan, Mutang Li, Dan-Dan Luo et al.· Materials Today Bio· 0 citations
This review synthesizes recent advances in molecular engineering strategies that enhance CAR-T cell function beyond conventional receptor design and discusses how receptor engineering, genome editing, transcriptional and epigenetic regulation, metabolic reprogramming, synthetic gene circuits, and safety-control platfor...
Hany E. Marei, G. Pozzoli, S. Caratelli et al.· Stem cell research & therape...· 0 citations
OutLAST Regulators are designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence and are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enh...
S. Boyken, Sean A. Merillat, Robert A. Langan et al.· bioRxiv· 0 citations
Developing a mechanistic framework that combines intrinsic T cell reprogramming with adaptation to the tumor context will be crucial for extending durable T cell-mediated immunity to solid cancers.
Hojin Chun, Hyunjin Ju, S. Hwang· BMB Reports· 0 citations
This review highlights key engineering strategies enabling in vivo CAR T-cell generation, summarizes emerging clinical research and development, and discusses future opportunities for expanding in vivo CAR T-cell therapies as scalable immunotherapy platforms.
Janani Gopalakrishnan, Bhagyashri Rathod, Sachin Puri· International Immunopharmaco...· 0 citations
A Quality-by-Design (QbD) framework is proposed-a systematic, science- and risk-based development approach that begins with predefined product objectives and links critical quality attributes to material attributes and process controls and discusses development pathways that emphasize platform–indication matching, inna...
David F. Stroncek, Jia-Qiang Ren, Anh Dinh· Translational Insights· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
